![Filip Janku](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Filip Janku
Chief Tech/Sci/R&D Officer at
MONTE ROSA THERAPEUTICS, INC.
Net worth: 154 467 $ as of 2026-05-30
Profile
Dr. Filip Janku is a Chief Medical Officer at Monte Rosa Therapeutics, Inc. Dr. Janku was previously employed as a Center Medical Director & Associate Professor by The University of Texas M.D.
Anderson Cancer Center.
He received his doctorate degree from the University of Charles.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-30 | 7,837 ( 0.01% ) | 154 467 $ | 2026-05-30 |
Filip Janku active positions
| Companies | Position | Start |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-05-31 |
Former positions of Filip Janku
| Companies | Position | End |
|---|---|---|
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Corporate Officer/Principal | 2021-04-30 |
Training of Filip Janku
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
5
1st degree connections
3
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
University of Charles
 University of Charles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
- Stock Market
- Insiders
- Filip Janku
